JOHNSON & JOHNSON (JNJ)
Johnson & Johnsons Phase 3 prostate cancer study shows ERLEADA® (apalutamide) before and after surgery significantly reduces risk of metastasis or death, breaking a decades-long treatment paradigm
Johnson & Johnsons Phase 3 prostate cancer study shows ERLEADA® (apalutamide) before and after surgery significantly reduces risk of metastasis or death, breaking a decades-long treatment paradigm
📈 **POSITIVE** • Medium confidence analysis (79%) • Strong positive business development • Significant competitive advantage **Sentiment:** Positive (95%) **Content type:** Business